Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series
Rhea-AI Summary
Phio Pharmaceuticals (NASDAQ: PHIO) will participate in Renmark Financial Communications’ live Virtual Non-Deal Roadshow Series on Tuesday, July 28, 2026, at 12 PM EDT. CEO and Chairman Robert Bitterman will present an overview of the company’s proprietary INTASYL® siRNA gene silencing platform, highlighting lead clinical candidate PH-762 for cutaneous carcinomas, followed by a live Q&A session with investors. This announcement corrects the previously misstated day of the week. A replay may be available on Renmark’s website. Phio describes PH-762, which silences the PD-1 gene, as a potential non-surgical treatment for various skin cancers.
Positive
- None.
Negative
- None.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Jul 21 | Board appointment | Positive | +4.6% | Dermatologist and former FDA advisory committee member joined Phio's board. |
| Jul 15 | Patent milestone | Positive | -13.6% | Three patent allowances and one grant decision expanded INTASYL intellectual property protection. |
| Jun 26 | Investor roadshow | Neutral | +1.1% | Phio announced a June 30 presentation covering INTASYL and lead candidate PH-762. |
| Jun 25 | Fireside chat | Neutral | -5.9% | Management scheduled a virtual discussion covering siRNA therapy and skin cancer treatments. |
| Jun 24 | Manufacturing milestone | Positive | -1.9% | Commercial-scale cGMP production began to support PH-762's next clinical development phase. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
PHIO's recent communications and development announcements produced mixed reactions, including positive, negative, and near-flat responses.
Key Terms
sirna technical
gene silencing medical
immuno-oncology medical
pd-1 medical
phase 1b medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
Live Presentation and Q&A: Tuesday, July 28, 2026 12 PM EDT
King of Prussia, Pennsylvania--(Newsfile Corp. - July 22, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio Pharmaceuticals announced today that Robert Bitterman, CEO and Chairman of the Board, will present an overview of the Company's INTASYL® siRNA platform, including its lead clinical candidate PH-762 for the treatment of cutaneous carcinomas. The presentation will be followed by a live Q&A session. This release corrects the day of the week that the presentation will be held. The presentation will be held on Tuesday on July 28, 2026 at 12 PM EDT.
"We look forward to engaging with investors at the Renmark Financial Virtual Non-Deal Roadshow and sharing our perspective on how INTASYL may offer a unique and promising approach to advancing immuno-oncology therapies," said Robert Bitterman, CEO and Chairman of Phio Pharmaceuticals.
Phio's presentation and live Q&A will take place on Tuesday July 28, 2026, at 12 PM EDT in the live Virtual Non-Deal Roadshow Series hosted by Renmark Financial Communications Inc.
REGISTER HERE: Renmark Virtual Non-Deal Roadshow NASDAQ - PHIO | Register | Renmark
Please Note: If the link does not work, please copy and paste into your browser. To ensure smooth connectivity, please access the link above using the latest version of Google Chrome.
A replay of the event may be accessed on the Renmark Financial Communications Inc. website at https://www.renmarkfinancial.com/vndrs.
Phio Pharmaceuticals Corp. (Nasdaq: PHIO) is a clinical-stage biopharmaceutical company advancing its proprietary INTASYL® siRNA gene silencing technology to eliminate cancer. Phio's INTASYL compounds are designed to enhance the body's immune cells to more effectively kill cancer cells. Phio's lead clinical development program is an INTASYL compound, PH-762, that silences the PD-1 gene implicated in various forms of skin cancer. The Phase 1b trial (NCT# 06014086) evaluated PH-762 for the treatment of cutaneous squamous cell carcinoma, melanoma and Merkel cell carcinoma. PH-762 is a potential non-surgical treatment for skin cancers.
For additional information, visit the Company's website, www.phiopharma.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as "intends," "believes," "anticipates," "indicates," "plans," "expects," "suggests," "may," "would," "should," "potential," "designed to," "will," "ongoing," "estimate," "forecast," "target," "predict," "could" and similar references, although not all forward-looking statements contain these words. These statements, which include statements, among other things, regarding the anticipated benefits of our INTASYL™ RNAi platform, the results from our ongoing clinical trials, our expectations regarding timing of FDA submissions intended to propose and seek guidance for next steps in clinical study design for PH-762, our expectations that such FDA submissions and any related FDA meetings will clarify next steps in advancing the PH-762 development program, details regarding our planned non-clinical toxicology study, and our ability to support ongoing clinical development, operational requirements and strategic initiatives with the capital we currently have on hand, are based only on our current beliefs, expectations and assumptions and are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results may differ materially from those indicated in the forward-looking statements as a result of a number of important factors, including, but not limited to, the impact of future FDA interactions on the development of our product candidates; the impact to our business and operations by inflationary pressures; recession fears; the development of our product candidates, results from our nonclinical, preclinical and clinical activities, our ability to execute on business strategies, our ability to develop our product candidates with collaboration partners, and the success of any such collaborations, the timeline and duration for advancing our product candidates into clinical development, the timing or likelihood of regulatory filings and approvals, the success of our efforts to commercialize our product candidates if approved, our ability to manufacture and supply our product candidates for clinical activities, and for commercial use if approved, the scope of protection we are able to establish and maintain for intellectual property rights covering our technology platform, our ability to obtain future financing, market and other conditions and those risks identified in our most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q under the caption "Risk Factors" and in other filings the Company periodically makes with the U.S. Securities and Exchange Commission. Readers are urged to review these risk factors and to not act in reliance on any forward-looking statements, as actual results may differ from those contemplated by our forward-looking statements. Phio does not undertake to update forward-looking statements to reflect a change in its views, events or circumstances that occur after the date of this release, except as required by law.
Contact:
Phio Pharmaceuticals Corp.
Jennifer Phillips: jphillips@phiopharma.com
Corporate Affairs
Renmark Financial Communications Inc.
James R. Kautz: jkautz@renmarkfinancial.com
Tel: (416)-644-2020 or (212)-812-7680
www.renmarkfinancial.com
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/306096